Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/sage/new-agents-on-the-horizon-in-hepatocellular-carcinoma-0oVsHWAslF
References (49)
-
A. Zhu, R. Finn, M. Mulcahy, J. Gurtler, Weijing Sun, J. Schwartz, P. Rojas, A. Dontabhaktuni, H. Youssoufian, K. Stuart (2010)
A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).Journal of Clinical Oncology, 28
-
Hideaki Miura, T. Miyazaki, M. Kuroda, Teruaki Oka, R. Machinami, Tatsuhiko Kodama, M. Shibuya, M. Makuuchi, Y. Yazaki, S. Ohnishi (1997)
Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma.Journal of hepatology, 27 5
-
T. Yau, Pei‐Jer Chen, P. Chan, C. Curtis, P. Murphy, A. Suttle, J. Gauvin, J. Hodge, M. Dar, R. Poon (2011)
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and PharmacodynamicsClinical Cancer Research, 17
-
D. Parkin, F. Bray, J. Ferlay, P. Pisani (2005)
Global Cancer Statistics, 2002CA: A Cancer Journal for Clinicians, 55
-
A. Kiss, Nengjin Wang, Jin-Ping Xie, S. Thorgeirsson (1997)
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research, 3 7
-
K. Jeng, I. Sheen, Yi-Ching Wang, S. Gu, C. Chu, S. Shih, Po-Chuan Wang, Wen-Hsing Chang, Horng‐Yuan Wang (2004)
Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study.World journal of gastroenterology, 10 5
-
A. Zhu, D. Sahani, D. Duda, E. Tomaso, M. Ancukiewicz, O. Catalano, V. Sindhwani, L. Blaszkowsky, Sam Yoon, J. Lahdenranta, P. Bhargava, J. Meyerhardt, Jeffrey Clark, E. Kwak, A. Hezel, R. Miksad, T. Abrams, P. Enzinger, C. Fuchs, D. Ryan, R. Jain (2009)
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18
-
T. Bekaii-Saab, J. Markowitz, Nichole Prescott, W. Sadee, N. Heerema, Lai Wei, Zunyan Dai, A. Papp, A. Campbell, K. Culler, C. Balint, B. O'Neil, Ruey-min Lee, M. Zalupski, J. Dancey, He Chen, M. Grever, C. Eng, M. Villalona-Calero (2009)
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular CarcinomasClinical Cancer Research, 15
-
S. Alberts, T. Fitch, George Kim, B. Morlan, S. Dakhil, H. Gross, S. Nair (2012)
Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical TrialAmerican Journal of Clinical Oncology, 35
-
A. Villanueva, Derek Chiang, P. Newell, J. Peix, S. Thung, Clara Alsinet, V. Tovar, S. Roayaie, B. Mínguez, M. Solé, C. Battiston, S. Laarhoven, M. Fiel, Analisa Feo, Y. Hoshida, S. Yea, S. Toffanin, A. Ramos, J. Martignetti, V. Mazzaferro, J. Bruix, S. Waxman, M. Schwartz, M. Meyerson, S. Friedman, J. Llovet (2008)
Pivotal role of mTOR signaling in hepatocellular carcinoma.Gastroenterology, 135 6
-
F. Kanai, H. Yoshida, R. Tateishi, Shin'pei Sato, T. Kawabe, S. Obi, Yuji Kondo, M. Taniguchi, K. Tagawa, M. Ikeda, C. Morizane, T. Okusaka, H. Arioka, S. Shiina, M. Omata (2011)
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinomaCancer Chemotherapy and Pharmacology, 67
-
O. Press, J. Unger, R. Braziel, D. Maloney, T. Miller, M. LeBlanc, R. Fisher (2006)
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 25
-
Yasuhiro Ito, T. Takeda, S. Higashiyama, M. Sakon, K. Wakasa, M. Tsujimoto, M. Monden, N. Matsuura (2001)
Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study.Oncology reports, 8 4
-
R. Yamaguchi, H. Yano, Y. Nakashima, S. Ogasawara, K. Higaki, J. Akiba, D. Hicklin, M. Kojiro (2000)
Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.Oncology reports, 7 4
-
P. O’Dwyer, B. Giantonio, D. Levy, J. Kauh, D. Fitzgerald, A. Benson (2006)
Gefitinib in advanced unresectable hepatocellular carcinoma: Results from the Eastern Cooperative Oncology Group's Study E1203.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
H. Huynh, V. Ngo, J. Fargnoli, M. Ayers, K. Soo, H. Koong, C. Thng, H. Ong, A. Chung, P. Chow, P. Pollock, S. Byron, E. Tran (2008)
Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular CarcinomaClinical Cancer Research, 14
-
R. Ramanathan, C. Belani, Deepti Singh, Michael Tanaka, H. Lenz, Y. Yen, H. Kindler, S. Iqbal, J. Longmate, P. Mack, G. Lurje, R. Gandour-Edwards, J. Dancey, D. Gandara (2009)
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerCancer Chemotherapy and Pharmacology, 64
-
J. Garcia, L. Roberts (2012)
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.Journal of hepatology, 56 2
-
A. Zhu, T. Abrams, R. Miksad, L. Blaszkowsky, J. Meyerhardt, Hui Zheng, A. Muzikansky, Jeffrey Clark, E. Kwak, D. Schrag, Kathryn Jors, C. Fuchs, A. Iafrate, D. Borger, D. Ryan (2011)
Phase 1/2 study of everolimus in advanced hepatocellular carcinomaCancer, 117
-
D. Koeberle, M. Montemurro, P. Samaras, P. Majno, M. Simcock, A. Limacher, S. Lerch, K. Kovács, R. Inauen, V. Hess, P. Saletti, M. Borner, A. Roth, G. Bodoky (2010)
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).The oncologist, 15 3
-
R. Finn, Yoon-Koo Kang, M. Mulcahy, B. Polite, Ho Lim, I. Walters, C. Baudelet, Demetrios Manekas, Joong-Won Park (2011)
Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 18
-
K. Harada, G. Shiota, H. Kawasaki (1999)
Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma.Liver, 19 4
-
Y. Yeh, J. Tsai, L. Chuang, H. Yeh, J. Tsai, D. Florine, J. Tam (1987)
Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma.Cancer research, 47 3
-
Y. Chao, Chung-Ping Li, G. Chau, Chih-Ping Chen, K. King, W. Lui, S. Yen, F. Chang, W. Chan, Shou-Dong Lee (2003)
Prognostic Significance of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Angiogenin in Patients With Resectable Hepatocellular Carcinoma After SurgeryAnnals of Surgical Oncology, 10
-
A. Cheng, Yoon-Koo Kang, D. Lin, Joong-Won Park, M. Kudo, S. Qin, Masao Omata, S. Lowenthal, S. Lanzalone, Liqiang Yang, M. Lechuga, E. Raymond (2011)
Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
R. Poon, J. Ho, C. Tong, C. Lau, I. Ng, S. Fan (2004)
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinomaBritish Journal of Surgery, 91
-
K. Okita, H. Kumada, K. Ikeda, M. Kudo, S. Kawazoe, Y. Osaki, M. Ikeda, T. Tamai, Takuya Suzuki (2012)
Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4_suppl
-
A. Zhu, D. Duda, D. Sahani, R. Jain (2011)
HCC and angiogenesis: possible targets and future directionsNature Reviews Clinical Oncology, 8
-
T. Pawson (2002)
Regulation and targets of receptor tyrosine kinases.European journal of cancer, 38 Suppl 5
-
S. Kira, T. Nakanishi, S. Suemori, M. Kitamoto, Yasuyuki. Watanabe, G. Kajiyama (2008)
Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma.Liver, 17 4
-
A. Siegel, E. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. Knox, Helen Chen, S. Clark-Garvey, A. Weinberg, J. Mandeli, P. Christos, M. Mazumdar, E. Popa, Robert Brown, S. Rafii, J. Schwartz (2008)
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 18
-
L. Chen, H. Shiah, C. Chen, Y. Lin, P. Lin, W. Su, J. Chang (2009)
Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
B. O'Neil, L. Goff, J. Kauh, J. Strosberg, T. Bekaii-Saab, Ruey-min Lee, Aslamuzzaman Kazi, D. Moore, M. Learoyd, R. Lush, S. Sebti, D. Sullivan (2011)
Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 17
-
H. Toh, Pei-Jer Chen, B. Carr, J. Knox, S. Gill, J. Steinberg, D. Carlson, J. Qian, Q. Qin, W. Yong (2009)
A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
P. Philip, M. Mahoney, C. Allmer, James Thomas, H. Pitot, George Kim, R. Donehower, T. Fitch, J. Picus, C. Erlichman (2005)
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 27
-
A. Arora, E. Scholar (2005)
Role of Tyrosine Kinase Inhibitors in Cancer TherapyJournal of Pharmacology and Experimental Therapeutics, 315
-
R. Yamaguchi, H. Yano, A. Iemura, S. Ogasawara, M. Haramaki, M. Kojiro (1998)
Expression of vascular endothelial growth factor in human hepatocellular carcinomaHepatology, 28
-
C. Carlin, T. Simon, J. Mattison, B. Knowles (1988)
Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell linesMolecular and Cellular Biology, 8
-
M. Thomas, Romil Chadha, K. Glover, Xuemei Wang, Jeffrey Morris, T. Brown, A. Rashid, J. Dancey, J. Abbruzzese (2007)
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinomaCancer, 110
-
(2004)
BMC Gastroenterology BioMed Central -
D. Mendel, A. Laird, Xiaohua Xin, S. Louie, J. Christensen, Guangmin Li, R. Schreck, T. Abrams, T. Ngai, Leslie Lee, Lesley Murray, J. Carver, E. Chan, K. Moss, J. Haznedar, J. Sukbuntherng, R. Blake, Li Sun, C. Tang, T. Miller, Sheri Shirazian, G. Mcmahon, J. Cherrington (2003)
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 1
-
A. Zhu, K. Stuart, L. Blaszkowsky, A. Muzikansky, D. Reitberg, Jeffrey Clark, P. Enzinger, P. Bhargava, J. Meyerhardt, K. Horgan, C. Fuchs, D. Ryan (2007)
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaCancer, 110
-
S. Chan, H. Chung, Lingzhi Wang, R. Lim, J. Picus, M. Boyer, C. Erlichman, A. Chan, B. Goh, W. Yeo (2012)
Efficacy of belinostat in advanced hepatocellular carcinoma (HCC): Phase I and II multicentered study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4_suppl
-
A. Cohn, R. Kelley, T.S. Yang, W. Su, C. Verslype, D. Ramies, Yihua Lee, Xiao-dong Shen, E. Cutsem (2012)
Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 4_suppl
-
S. Faivre, E. Raymond, E. Boucher, J. Douillard, Ho Lim, Jun Kim, M. Zappa, S. Lanzalone, Xun Lin, S. Deprimo, C. Harmon, A. Ruiz-Garcia, M. Lechuga, A. Cheng (2009)
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.The Lancet. Oncology, 10 8
-
D. Koeberle, M. Montemurro, Panagiotis Samaras, Pietro Majno, M. Simcock, K. Kovács, R. Inauen, V. Hess, P. Saletti, G. Bodoky (2009)
Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trial (SAKK 77/06 and SASL 23).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
L. Messerini, L. Novelli, C. Comin (2004)
Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinomaJournal of Clinical Pathology, 57
-
S. Wedge, J. Kendrew, L. Hennequin, P. Valentine, S. Barry, S. Brave, N. Smith, N. James, M. Dukes, J. Curwen, R. Chester, J. Jackson, S. Boffey, Lyndsey Kilburn, S. Barnett, Graham Richmond, P. Wadsworth, Mike Walker, Alison Bigley, S. Taylor, L. Cooper, Sarah Beck, J. Jürgensmeier, D. Ogilvie (2005)
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.Cancer research, 65 10
-
V. Gruenwald, L. Wilkens, M. Gebel, T. Greten, S. Kubicka, A. Ganser, M. Manns, N. Malek (2007)
A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final resultsJournal of Clinical Oncology, 25
- Publisher
- SAGE
- Copyright
- Copyright © 2020 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
- ISSN
- 1758-8359
- eISSN
- 1758-8359
- DOI
- 10.1177/1758834012458480
- Publisher site
- See Article on Publisher Site
Abstract
Despite the successful approval and extensive application of sorafenib, the prognosis for patients with advanced hepatocellular carcinoma (HCC) remains poor. Fortunately, there have been renewed and continued interests and active research in developing other molecularly targeted agents in HCC during the past few years. While there is early evidence of antitumor activity of several agents in phase I/II studies, phase III efforts with a few targeted agents have failed, highlighting the challenges of new drug development in HCC. This review summarizes the current status of other molecularly targeted agents under development in advanced HCC.
Journal
Therapeutic Advances in Medical Oncology – SAGE
Published: Aug 24, 2012
Keywords: bevacizumab,brivanib,EGFR inhibitors,everolimus,hepatocellular carcinoma,linifanib,Met inhibitors,sorafenib,sunitinib,targeted agents